Ticker Appearances
Daily Technical Strategy
Tech Hardware favored over Software; Meanwhile Pharma/Biotech slides further
NEAR-TERM AND INTERMEDIATE-TERM TECHNICAL TRENDS REMAIN BULLISH FOR US EQUITIES, AND WEDNESDAY’S BOUNCE MADE SUFFICIENT PROGRESS TO HELP ESTABLISH A NEW SHORT-TERM UPTREND, WHICH ARGUABLY...
Unlock full access to Fundstrat’s research — now at our lowest price of 2025.
You’ve reached your 5 free reports this month.
Visitor: d682ee-7ce8b6-67145d-f85a3f-f460c2 Array ( [cookie] => d682ee-7ce8b6-67145d-f85a3f-f460c2 [current_usage] => 5 [max_usage] => 2 [current_usage_crypto] => 2 [max_usage_crypto] => 2 [lock] => 1 [message] => [error] => [active_member] => 0 [subscriber] => 0 [role] => [user_id] => [IP] => 216.73.216.41 )
Your Weekly Roadmap
Stocks’ Continued Strength Bodes Well For 2nd Half
"An investment in knowledge pays the best interest." — Benjamin Franklin Good evening: For months, our Tom Lee has said inflation would fall throughout 2023...
Unlock full access to Fundstrat’s research — now at our lowest price of 2025.
You’ve reached your 5 free reports this month.
Visitor: d682ee-7ce8b6-67145d-f85a3f-f460c2 Array ( [cookie] => d682ee-7ce8b6-67145d-f85a3f-f460c2 [current_usage] => 5 [max_usage] => 2 [current_usage_crypto] => 2 [max_usage_crypto] => 2 [lock] => 1 [message] => [error] => [active_member] => 0 [subscriber] => 0 [role] => [user_id] => [IP] => 216.73.216.41 )
Daily Technical Strategy
Tech Hardware favored over Software; Meanwhile Pharma/Biotech slides further
NEAR-TERM AND INTERMEDIATE-TERM TECHNICAL TRENDS REMAIN BULLISH FOR US EQUITIES, AND WEDNESDAY’S BOUNCE MADE SUFFICIENT PROGRESS TO HELP ESTABLISH A NEW SHORT-TERM UPTREND, WHICH ARGUABLY...
Unlock full access to Fundstrat’s research — now at our lowest price of 2025.
You’ve reached your 5 free reports this month.
Visitor: d682ee-7ce8b6-67145d-f85a3f-f460c2 Array ( [cookie] => d682ee-7ce8b6-67145d-f85a3f-f460c2 [current_usage] => 5 [max_usage] => 2 [current_usage_crypto] => 2 [max_usage_crypto] => 2 [lock] => 1 [message] => [error] => [active_member] => 0 [subscriber] => 0 [role] => [user_id] => [IP] => 216.73.216.41 )
Your Weekly Roadmap
Stocks’ Continued Strength Bodes Well For 2nd Half
"An investment in knowledge pays the best interest." — Benjamin Franklin Good evening: For months, our Tom Lee has said inflation would fall throughout 2023...
Unlock full access to Fundstrat’s research — now at our lowest price of 2025.
You’ve reached your 5 free reports this month.
Visitor: d682ee-7ce8b6-67145d-f85a3f-f460c2 Array ( [cookie] => d682ee-7ce8b6-67145d-f85a3f-f460c2 [current_usage] => 5 [max_usage] => 2 [current_usage_crypto] => 2 [max_usage_crypto] => 2 [lock] => 1 [message] => [error] => [active_member] => 0 [subscriber] => 0 [role] => [user_id] => [IP] => 216.73.216.41 )
Daily Technical Strategy
Tech Hardware favored over Software; Meanwhile Pharma/Biotech slides further
NEAR-TERM AND INTERMEDIATE-TERM TECHNICAL TRENDS REMAIN BULLISH FOR US EQUITIES, AND WEDNESDAY’S BOUNCE MADE SUFFICIENT PROGRESS TO HELP ESTABLISH A NEW SHORT-TERM UPTREND, WHICH ARGUABLY...
Unlock full access to Fundstrat’s research — now at our lowest price of 2025.
You’ve reached your 5 free reports this month.
Visitor: d682ee-7ce8b6-67145d-f85a3f-f460c2 Array ( [cookie] => d682ee-7ce8b6-67145d-f85a3f-f460c2 [current_usage] => 5 [max_usage] => 2 [current_usage_crypto] => 2 [max_usage_crypto] => 2 [lock] => 1 [message] => [error] => [active_member] => 0 [subscriber] => 0 [role] => [user_id] => [IP] => 216.73.216.41 )
Articles Read 2/2
🎁 Unlock 1 extra article by joining our Community!
You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.
Already have an account? Sign In d682ee-7ce8b6-67145d-f85a3f-f460c2
Already have an account? Sign In d682ee-7ce8b6-67145d-f85a3f-f460c2
